CE contact hours are no longer available for the content covered in this podcast episode. Check out the online library at pcna.net for up-to-date CE offerings.

Often prescribed for obesity, SGLT2is and GLP-1 RAs have a role in heart failure management. Learn about their mechanisms of action, and how their use extends beyond weight loss to cardioprotective and renalprotective properties. Guests: Kim Newlin, MSN, ANP, FPCNA, of Sutter Roseville Medical Center in Northern California, and Colleen McIlvennan, PhD, DNP, ANP, FAHA, FHFSA, from the University of Colorado in Denver.

2022 AHA/ACC/HFSA 2022 Guideline for the Managment of HF: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063

Pocket Guide: Guidelines for Managing CVD Risk in Patients with Diabetes: https://pcna.net/clinical-resources/provider-tools/diabetes-provider-tools/

HF Pocket Guide: A Guide to Prevention and Management: https://pcna.net/clinical-resources/provider-tools/heart-failure-provider-tools/

New and Emerging Treatments for Heart Failure: HFrEF and HFpEF (CE course): https://pcna.net/online-course/new-and-emerging-treatments-for-heart-failure-hfref-and-hfpef/

SGLT2is in Heart Failure: ncbi.nlm.nih.gov/pmc/articles/PMC8654149/

SGLT2i in HFpEF: multicenter randomized trial: nature.com/articles/s41591-021-01536-x

Empagliflozin in HFpEF: https://www.nejm.org/doi/10.1056/NEJMoa2107038#:~:text=Empagliflozin%20in%20HF%20with%20Preserved%20Ejection%20Fraction&text=Sodium%E2%80%93glucose%20cotransporter%202%20(SGLT2,and%20a%20reduced%20ejection%20fraction.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.